These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

451 related items for PubMed ID: 25055259

  • 1. Journal Club: Diagnostic value of (18)F-FDG PET/CT and MRI in predicting the clinicopathologic subtypes of invasive breast cancer.
    Miyake KK, Nakamoto Y, Kanao S, Tanaka S, Sugie T, Mikami Y, Toi M, Togashi K.
    AJR Am J Roentgenol; 2014 Aug; 203(2):272-9. PubMed ID: 25055259
    [Abstract] [Full Text] [Related]

  • 2. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
    Ohara M, Shigematsu H, Tsutani Y, Emi A, Masumoto N, Ozaki S, Kadoya T, Okada M.
    Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
    [Abstract] [Full Text] [Related]

  • 3. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S, Chen W, Tchou J, Mavi A, Cermik T, Czerniecki B, Schnall M, Alavi A.
    Cancer; 2008 Mar 01; 112(5):995-1000. PubMed ID: 18098228
    [Abstract] [Full Text] [Related]

  • 4. The maximum standardized uptake value of metastatic site in 18 F-FDG PET/CT predicts molecular subtypes and survival in metastatic breast cancer: An Izmir Oncology Group study.
    Cokmert S, Tanriverdi O, Karapolat I, Demir L, Bayoglu V, Can A, Akyol M, Yilmaz Y, Oktay Tarhan M.
    J BUON; 2016 Mar 01; 21(6):1410-1418. PubMed ID: 28039701
    [Abstract] [Full Text] [Related]

  • 5. Assessment of combination of contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography for evaluation of ovarian masses.
    Tsuboyama T, Tatsumi M, Onishi H, Nakamoto A, Kim T, Hori M, Sakane M, Hori Y, Morii E, Hatazawa J, Tomiyama N.
    Invest Radiol; 2014 Aug 01; 49(8):524-31. PubMed ID: 24637584
    [Abstract] [Full Text] [Related]

  • 6. Invasive cribriform carcinoma of the breast: mammographic, sonographic, MRI, and 18 F-FDG PET-CT features.
    Lee YJ, Choi BB, Suh KS.
    Acta Radiol; 2015 Jun 01; 56(6):644-51. PubMed ID: 24938660
    [Abstract] [Full Text] [Related]

  • 7. CA 15.3 measurements for separating FDG PET/CT positive from negative findings in breast carcinoma recurrence. Factors influencing the area under the ROC curve.
    Kruse V, Van de Wiele C, Borms M, Maes A, Pottel H, Sathekge M, Cocquyt V.
    Nuklearmedizin; 2014 Aug 06; 53(4):131-8. PubMed ID: 25100557
    [Abstract] [Full Text] [Related]

  • 8. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.
    Breast; 2013 Oct 06; 22(5):691-7. PubMed ID: 23414930
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Combined 18F-FDG and 18F-Alfatide II PET May Predict Luminal B (HER2 Negative) Subtype and Nonluminal Subtype of Invasive Breast Cancer.
    Wu J, Zhang X, Jia Z, Zhou X, Qi R, Ji H, Sun J, Sun C, Teng Z, Lu G, Chen X.
    Mol Pharm; 2022 Sep 05; 19(9):3405-3411. PubMed ID: 35972444
    [Abstract] [Full Text] [Related]

  • 15. Correlation of the value of 18F-FDG uptake, described by SUVmax, SUVavg, metabolic tumour volume and total lesion glycolysis, to clinicopathological prognostic factors and biological subtypes in breast cancer.
    Kajáry K, Tőkés T, Dank M, Kulka J, Szakáll S, Lengyel Z.
    Nucl Med Commun; 2015 Jan 05; 36(1):28-37. PubMed ID: 25299471
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Associations between the standardized uptake value of (18)F-FDG PET/CT and the prognostic factors of invasive lobular carcinoma: in comparison with invasive ductal carcinoma.
    Jung NY, Kim SH, Choi BB, Kim SH, Sung MS.
    World J Surg Oncol; 2015 Mar 15; 13():113. PubMed ID: 25889560
    [Abstract] [Full Text] [Related]

  • 18. Does the pretreatment tumor sampling location correspond with metabolic activity on 18F-FDG PET/CT in breast cancer patients scheduled for neoadjuvant chemotherapy?
    Koolen BB, Elshof LE, Loo CE, Wesseling J, Vrancken Peeters MJ, Vogel WV, Rutgers EJ, Valdés Olmos RA.
    Eur J Radiol; 2013 Dec 15; 82(12):2353-8. PubMed ID: 23998705
    [Abstract] [Full Text] [Related]

  • 19. 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.
    Gebhart G, Gámez C, Holmes E, Robles J, Garcia C, Cortés M, de Azambuja E, Fauria K, Van Dooren V, Aktan G, Coccia-Portugal MA, Kim SB, Vuylsteke P, Cure H, Eidtmann H, Baselga J, Piccart M, Flamen P, Di Cosimo S.
    J Nucl Med; 2013 Nov 15; 54(11):1862-8. PubMed ID: 24092940
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.